Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label study of ferric derisomaltose (NS-32) vs saccharated iron oxide in iron deficiency anemia due to menorrhagia
jRCT2080224508Phase 3Completed
- Sponsor
- Nippon Shinyaku
- Start
- Jan 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Nippon Shinyaku. Primary endpoint: Maximum change in hemoglobin from baseline. Started Jan 2019; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on jRCT2080224508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224508.